US medical technology company Valeritas has developed a wearable insulin delivery device that provides type II diabetes patients with a low-dose, continuous supply of insulin, as well as intravenous insulin doses when required. The V-Go system adheres to a flat part of the body and can be filled by the user for both continuous supply and top-up bolus doses. In addition to providing an alternative method of delivering insulin in situations where traditional pumps are not available, the new product is also designed to provide more accurate dosing than current devices. However, V-Go does not replace the need for blood glucose monitoring. Rather, it provides a discrete baseline insulin dose with the ability to administer additional doses using a single delivery system.
US medical technology company Valeritas has developed a wearable insulin delivery device that provides type II diabetes patients with a low-dose, continuous supply of insulin, as well as intravenous insulin doses when required. The V-Go system adheres to a flat part of the body and can be filled by the user for both continuous supply and top-up bolus doses. Patients and their healthcare providers liaise to determine the appropriate insulin doses. However, V-Go does not replace the need for blood glucose monitoring. Rather, it provides a discrete baseline insulin dose with the ability to administer additional doses using a single delivery system.